Nonlinear Protein Binding: Not What You Think.
Nonlinear protein binding is traditionally thought of as an increasing fraction unbound with increasing total drug concentration. In the past several years, research into the protein binding of several tetracyclines has shown that an unexpected and counterintuitive phenomenon has been observed, specifically that of decreasing unbound drug fraction with increasing total concentrations of drug over certain concentration ranges. Although several studies of tigecycline have shown the importance calcium and its chelation may play in the protein-drug interaction, the potential clinical implications and relevance have not been explored. Here, we define typical and atypical nonlinear protein binding, overview protein binding theory, and discuss theoretical implications on pharmacokinetics. Using tigecycline as an example, in silico simulations and calculations show how when atypical nonlinear protein binding is not accounted for free drug exposure, and drug tissue penetration may be overestimated. It is important to revisit the impacts of nonlinearity in protein binding on clinical pharmacokinetics and pharmacodynamics, and ultimately, clinical efficacy. Although this phenomenon could potentially warrant clinical dose adjustment for certain compounds, it also presents a potential opportunity to exploit underlying mechanisms to develop new therapies and better understand molecular interactions of xenobiotics within the physiological system.
['Deitchman|Amelia N|AN|', 'Singh|Ravi Shankar Prasad|RSP|', 'Derendorf|Hartmut|H|']
D000818:Animals D000900:Anti-Bacterial Agents D006801:Humans D008954:Models, Biological D017711:Nonlinear Dynamics D004364:Pharmaceutical Preparations D010599:Pharmacokinetics D011485:Protein Binding D011506:Proteins D000078304:Tigecycline
protein binding clinical pharmacokinetics nonlinear pharmacokinetics